<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;ff=20240813021413&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;ff=20240813021413&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Tue, 13 Aug 2024 06:14:15 +0000</lastbuilddate>
<pubDate>Mon, 12 Aug 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Results of International, Double-Blind, Randomized, Placebo-Controlled, Phase IIa Study of Interleukin-1 Blockade With RPH-104 (Goflikicept) in Patients With ST-Segment-Elevation Myocardial Infarction (STEMI)</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39133774/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240813021413&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 13;150(7):580-582. doi: 10.1161/CIRCULATIONAHA.124.069396. Epub 2024 Aug 12.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39133774/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240813021413&v=2.18.0.post9+e462414">39133774</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069396>10.1161/CIRCULATIONAHA.124.069396</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39133774</guid>
<pubDate>Mon, 12 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Antonio Abbate</dc:creator>
<dc:creator>Benjamin Van Tassell</dc:creator>
<dc:creator>Vlad Bogin</dc:creator>
<dc:creator>Roshanak Markley</dc:creator>
<dc:creator>Dmitry V Pevzner</dc:creator>
<dc:creator>Paul C Cremer</dc:creator>
<dc:creator>Imad Meray</dc:creator>
<dc:creator>Dmitry V Privalov</dc:creator>
<dc:creator>Angela Taylor</dc:creator>
<dc:creator>Sergey A Grishin</dc:creator>
<dc:creator>Alina N Egorova</dc:creator>
<dc:creator>Ekaterina G Ponomar</dc:creator>
<dc:creator>Yan Lavrovsky</dc:creator>
<dc:creator>Mikhail Yu Samsonov</dc:creator>
<dc:creator>RPH-104 STEMI Study Investigators</dc:creator>
<dc:date>2024-08-12</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Results of International, Double-Blind, Randomized, Placebo-Controlled, Phase IIa Study of Interleukin-1 Blockade With RPH-104 (Goflikicept) in Patients With ST-Segment-Elevation Myocardial Infarction (STEMI)</dc:title>
<dc:identifier>pmid:39133774</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069396</dc:identifier>
</item>
<item>
<title>Cardio-Oncology: A New Clinical Frontier and Novel Platform for Cardiovascular Investigation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39133773/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240813021413&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 13;150(7):513-515. doi: 10.1161/CIRCULATIONAHA.124.065473. Epub 2024 Aug 12.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39133773/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240813021413&v=2.18.0.post9+e462414">39133773</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.065473>10.1161/CIRCULATIONAHA.124.065473</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39133773</guid>
<pubDate>Mon, 12 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Javid J Moslehi</dc:creator>
<dc:date>2024-08-12</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Cardio-Oncology: A New Clinical Frontier and Novel Platform for Cardiovascular Investigation</dc:title>
<dc:identifier>pmid:39133773</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.065473</dc:identifier>
</item>
<item>
<title>Letter by Soltani-Kermanshahi Regarding Article, "ChaMP-CMD: A Phenotype-Blinded, Randomized Controlled, Cross-Over Trial"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39133772/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240813021413&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 13;150(7):e155. doi: 10.1161/CIRCULATIONAHA.124.069134. Epub 2024 Aug 12.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39133772/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240813021413&v=2.18.0.post9+e462414">39133772</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069134>10.1161/CIRCULATIONAHA.124.069134</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39133772</guid>
<pubDate>Mon, 12 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Mojtaba Soltani-Kermanshahi</dc:creator>
<dc:date>2024-08-12</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Soltani-Kermanshahi Regarding Article, "ChaMP-CMD: A Phenotype-Blinded, Randomized Controlled, Cross-Over Trial"</dc:title>
<dc:identifier>pmid:39133772</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069134</dc:identifier>
</item>
<item>
<title>Pulmonary hypertension in heart failure: the good, the bad, and the ugly</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39132978/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240813021413&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 12:ehae518. doi: 10.1093/eurheartj/ehae518. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39132978/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240813021413&v=2.18.0.post9+e462414">39132978</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae518>10.1093/eurheartj/ehae518</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39132978</guid>
<pubDate>Mon, 12 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Stephan Rosenkranz</dc:creator>
<dc:creator>Marius M Hoeper</dc:creator>
<dc:creator>Bradley A Maron</dc:creator>
<dc:date>2024-08-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Pulmonary hypertension in heart failure: the good, the bad, and the ugly</dc:title>
<dc:identifier>pmid:39132978</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae518</dc:identifier>
</item>
<item>
<title>The DanGer Shock trial: a new dawn but much to uncover</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39132927/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240813021413&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 12:ehae516. doi: 10.1093/eurheartj/ehae516. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39132927/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240813021413&v=2.18.0.post9+e462414">39132927</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae516>10.1093/eurheartj/ehae516</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39132927</guid>
<pubDate>Mon, 12 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Enzo Lüsebrink</dc:creator>
<dc:creator>Leonhard Binzenhöfer</dc:creator>
<dc:creator>Holger Thiele</dc:creator>
<dc:date>2024-08-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The DanGer Shock trial: a new dawn but much to uncover</dc:title>
<dc:identifier>pmid:39132927</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae516</dc:identifier>
</item>
<item>
<title>The AORTA Gene score for detection and risk stratification of ascending aortic dilation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39132911/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240813021413&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: A comprehensive model incorporating polygenic information and clinical risk factors explained 34.9%-41.8% of the variation in ascending aortic diameter, improving the identification of ascending aortic dilation and adverse thoracic aortic events compared to clinical risk factors.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 12:ehae474. doi: 10.1093/eurheartj/ehae474. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: This study assessed whether a model incorporating clinical features and a polygenic score for ascending aortic diameter would improve diameter estimation and prediction of adverse thoracic aortic events over clinical features alone.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Aortic diameter estimation models were built with a 1.1 million-variant polygenic score (AORTA Gene) and without it. Models were validated internally in 4394 UK Biobank participants and externally in 5469 individuals from Mass General Brigham (MGB) Biobank, 1298 from the Framingham Heart Study (FHS), and 610 from All of Us. Model fit for adverse thoracic aortic events was compared in 401 453 UK Biobank and 164 789 All of Us participants.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: AORTA Gene explained more of the variance in thoracic aortic diameter compared to clinical factors alone: 39.5% (95% confidence interval 37.3%-41.8%) vs. 29.3% (27.0%-31.5%) in UK Biobank, 36.5% (34.4%-38.5%) vs. 32.5% (30.4%-34.5%) in MGB, 41.8% (37.7%-45.9%) vs. 33.0% (28.9%-37.2%) in FHS, and 34.9% (28.8%-41.0%) vs. 28.9% (22.9%-35.0%) in All of Us. AORTA Gene had a greater area under the receiver operating characteristic curve for identifying diameter ≥ 4 cm: 0.836 vs. 0.776 (P &lt; .0001) in UK Biobank, 0.808 vs. 0.767 in MGB (P &lt; .0001), 0.856 vs. 0.818 in FHS (P &lt; .0001), and 0.827 vs. 0.791 (P = .0078) in All of Us. AORTA Gene was more informative for adverse thoracic aortic events in UK Biobank (P = .0042) and All of Us (P = .049).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: A comprehensive model incorporating polygenic information and clinical risk factors explained 34.9%-41.8% of the variation in ascending aortic diameter, improving the identification of ascending aortic dilation and adverse thoracic aortic events compared to clinical risk factors.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39132911/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240813021413&v=2.18.0.post9+e462414">39132911</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae474>10.1093/eurheartj/ehae474</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39132911</guid>
<pubDate>Mon, 12 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>James P Pirruccello</dc:creator>
<dc:creator>Shaan Khurshid</dc:creator>
<dc:creator>Honghuang Lin</dc:creator>
<dc:creator>Lu-Chen Weng</dc:creator>
<dc:creator>Siavash Zamirpour</dc:creator>
<dc:creator>Shinwan Kany</dc:creator>
<dc:creator>Avanthi Raghavan</dc:creator>
<dc:creator>Satoshi Koyama</dc:creator>
<dc:creator>Ramachandran S Vasan</dc:creator>
<dc:creator>Emelia J Benjamin</dc:creator>
<dc:creator>Mark E Lindsay</dc:creator>
<dc:creator>Patrick T Ellinor</dc:creator>
<dc:date>2024-08-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The AORTA Gene score for detection and risk stratification of ascending aortic dilation</dc:title>
<dc:identifier>pmid:39132911</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae474</dc:identifier>
</item>
<item>
<title>Window of opportunity for developing effective medical intervention for calcific aortic valve disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39132886/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240813021413&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 12:ehae426. doi: 10.1093/eurheartj/ehae426. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39132886/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240813021413&v=2.18.0.post9+e462414">39132886</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae426>10.1093/eurheartj/ehae426</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39132886</guid>
<pubDate>Mon, 12 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>François Mach</dc:creator>
<dc:creator>Kapka Miteva</dc:creator>
<dc:date>2024-08-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Window of opportunity for developing effective medical intervention for calcific aortic valve disease</dc:title>
<dc:identifier>pmid:39132886</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae426</dc:identifier>
</item>
<item>
<title>Mineralocorticoid Receptor Antagonism Prevents Aortic Plaque Progression and Reduces Left Ventricular Mass and Fibrosis in Patients With Type 2 Diabetes and Chronic Kidney Disease: The MAGMA Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39129649/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240813021413&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Among patients with diabetes with moderate to severe chronic kidney disease at elevated cardiovascular risk, treatment with spironolactone prevented progression of aortic wall volume and resulted in regression of LV mass and favorable alterations in native T1, suggesting amelioration of left-ventricular fibrosis.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 12. doi: 10.1161/CIRCULATIONAHA.123.067620. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Persistent mineralocorticoid receptor activation is a pathologic response in type 2 diabetes and chronic kidney disease. Whereas mineralocorticoid receptor antagonists are beneficial in reducing cardiovascular complications, direct mechanistic pathways for these effects in humans are lacking.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The MAGMA trial (Mineralocorticoid Receptor Antagonism Clinical Evaluation in Atherosclerosis) was a randomized, double-blind, placebo-controlled trial in patients with high-risk type 2 diabetes with chronic kidney disease (not receiving dialysis) on maximum tolerated renin-angiotensin system blockade. The primary end point was change in thoracic aortic wall volume, expressed as absolute or percent value (ΔTWV or ΔPWV), using 3T magnetic resonance imaging at 12 months. Secondary end points were changes in left ventricle (LV) mass; LV fibrosis, measured as a change in myocardial native T1; and 24-hour ambulatory and central aortic blood pressures. Tertiary end points included plasma proteomic changes in 7596 plasma proteins using an aptamer-based assay.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 79 patients were randomized to placebo (n=42) or 25 mg of spironolactone daily (n=37). After a modified intent-to-treat, including available baseline data of study end points, patients who completed the trial protocol were included in the final analyses. At the 12-month follow-up, the average change in PWV was 7.1±10.7% in the placebo group and 0.87±10.0% in the spironolactone group (<i>P</i>=0.028), and ΔTWV was 1.2±1.7 cm<sup>3</sup> in the placebo group and 0.037±1.9 cm<sup>3</sup> in the spironolactone group (<i>P</i>=0.022). Change in LV mass was 3.1±8.4 g in the placebo group and -5.8±8.4 g in the spironolactone group (<i>P</i>=0.001). Changes in LV T1 values were significantly different between the placebo and spironolactone groups (26.0±41.9 ms in the placebo group versus a decrease of -10.1±36.3 ms in the spironolactone group; <i>P</i>=6.33×10<sup>-4</sup>). Mediation analysis revealed that the spironolactone effect on thoracic aortic wall volume and myocardial mass remained significant after adjustment for ambulatory and central blood pressures. Proteomic analysis revealed a dominant effect of spironolactone on pathways involving oxidative stress, inflammation, and leukocyte activation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Among patients with diabetes with moderate to severe chronic kidney disease at elevated cardiovascular risk, treatment with spironolactone prevented progression of aortic wall volume and resulted in regression of LV mass and favorable alterations in native T1, suggesting amelioration of left-ventricular fibrosis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02169089.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39129649/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240813021413&v=2.18.0.post9+e462414">39129649</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067620>10.1161/CIRCULATIONAHA.123.067620</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39129649</guid>
<pubDate>Mon, 12 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Sanjay Rajagopalan</dc:creator>
<dc:creator>Mirela Dobre</dc:creator>
<dc:creator>Jean-Eudes Dazard</dc:creator>
<dc:creator>Armando Vergara-Martel</dc:creator>
<dc:creator>Kim Connelly</dc:creator>
<dc:creator>Michael E Farkouh</dc:creator>
<dc:creator>Juan Gaztanaga</dc:creator>
<dc:creator>Heather Conger</dc:creator>
<dc:creator>Ann Dever</dc:creator>
<dc:creator>Laleh Razavi-Nematollahi</dc:creator>
<dc:creator>Anas Fares</dc:creator>
<dc:creator>Gabriel Pereira</dc:creator>
<dc:creator>Jonnelle Edwards-Glenn</dc:creator>
<dc:creator>Mark Cameron</dc:creator>
<dc:creator>Cheryl Cameron</dc:creator>
<dc:creator>Sadeer Al-Kindi</dc:creator>
<dc:creator>Robert D Brook</dc:creator>
<dc:creator>Bertram Pitt</dc:creator>
<dc:creator>Matthew Weir</dc:creator>
<dc:date>2024-08-12</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Mineralocorticoid Receptor Antagonism Prevents Aortic Plaque Progression and Reduces Left Ventricular Mass and Fibrosis in Patients With Type 2 Diabetes and Chronic Kidney Disease: The MAGMA Trial</dc:title>
<dc:identifier>pmid:39129649</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067620</dc:identifier>
</item>
<item>
<title>High-Throughput Deep Learning Detection of Mitral Regurgitation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39129623/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240813021413&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In this study, a novel automated pipeline for identifying clinically significant MR from full transthoracic echocardiography studies demonstrated excellent performance across large numbers of studies and across multiple institutions. Such an approach has the potential for automated screening and surveillance of MR.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 12. doi: 10.1161/CIRCULATIONAHA.124.069047. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Diagnosis of mitral regurgitation (MR) requires careful evaluation by echocardiography with Doppler imaging. This study presents the development and validation of a fully automated deep learning pipeline for identifying apical 4-chamber view videos with color Doppler echocardiography and detecting clinically significant (moderate or severe) MR from transthoracic echocardiograms.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A total of 58 614 transthoracic echocardiograms (2 587 538 videos) from Cedars-Sinai Medical Center were used to develop and test an automated pipeline to identify apical 4-chamber view videos with color Doppler across the mitral valve and then assess MR severity. The model was tested internally on a test set of 1800 studies (80 833 videos) from Cedars-Sinai Medical Center and externally evaluated in a geographically distinct cohort of 915 studies (46 890 videos) from Stanford Healthcare.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In the held-out Cedars-Sinai Medical Center test set, the view classifier demonstrated an area under the curve (AUC) of 0.998 (0.998-0.999) and correctly identified 3452 of 3539 echocardiography videos as having color Doppler information across the mitral valve (sensitivity of 0.975 [0.968-0.982] and specificity of 0.999 [0.999-0.999] compared with manually curated videos). In the external test cohort from Stanford Healthcare, the view classifier correctly identified 1051 of 1055 manually curated videos with color Doppler information across the mitral valve (sensitivity of 0.996 [0.990-1.000] and specificity of 0.999 [0.999-0.999]). In the Cedars-Sinai Medical Center test cohort, MR moderate or greater in severity was detected with an AUC of 0.916 (0.899-0.932) and severe MR was detected with an AUC of 0.934 (0.913-0.953). In the Stanford Healthcare test cohort, the model detected MR moderate or greater in severity with an AUC of 0.951 (0.924-0.973) and severe MR with an AUC of 0.969 (0.946-0.987).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In this study, a novel automated pipeline for identifying clinically significant MR from full transthoracic echocardiography studies demonstrated excellent performance across large numbers of studies and across multiple institutions. Such an approach has the potential for automated screening and surveillance of MR.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39129623/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240813021413&v=2.18.0.post9+e462414">39129623</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069047>10.1161/CIRCULATIONAHA.124.069047</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39129623</guid>
<pubDate>Mon, 12 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Amey Vrudhula</dc:creator>
<dc:creator>Grant Duffy</dc:creator>
<dc:creator>Milos Vukadinovic</dc:creator>
<dc:creator>David Liang</dc:creator>
<dc:creator>Susan Cheng</dc:creator>
<dc:creator>David Ouyang</dc:creator>
<dc:date>2024-08-12</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>High-Throughput Deep Learning Detection of Mitral Regurgitation</dc:title>
<dc:identifier>pmid:39129623</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069047</dc:identifier>
</item>
<item>
<title>Cardiovascular Management of Aortopathy in Children: A Scientific Statement From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39129620/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240813021413&amp;v=2.18.0.post9+e462414
      <description>Aortopathy encompasses a spectrum of conditions predisposing to dilation, aneurysm, dissection, or rupture of the aorta and other blood vessels. Aortopathy is diagnosed commonly in children, from infancy through adolescence, primarily affecting the thoracic aorta, with variable involvement of the peripheral vasculature. Pathogeneses include connective tissue disorders, smooth muscle contraction disorders, and congenital heart disease, including bicuspid aortic valve, among others. The American...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 12. doi: 10.1161/CIR.0000000000001265. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Aortopathy encompasses a spectrum of conditions predisposing to dilation, aneurysm, dissection, or rupture of the aorta and other blood vessels. Aortopathy is diagnosed commonly in children, from infancy through adolescence, primarily affecting the thoracic aorta, with variable involvement of the peripheral vasculature. Pathogeneses include connective tissue disorders, smooth muscle contraction disorders, and congenital heart disease, including bicuspid aortic valve, among others. The American Heart Association has published guidelines for diagnosis and management of thoracic aortic disease. However, these guidelines are predominantly focused on adults and cannot be applied adeptly to growing children with emerging features, growth and developmental changes, including puberty, and different risk profiles compared with adults. Management to reduce risk of progressive aortic dilation and dissection or rupture in children is complex and involves genetic testing, cardiovascular imaging, medical therapy, lifestyle modifications, and surgical guidance that differ in many ways from adult management. Pediatric practice varies widely, likely because aortopathy is pathogenically heterogeneous, including genetic and nongenetic conditions, and there is limited published evidence to guide care in children. To optimize care and reduce variation in management, experts in pediatric aortopathy convened to generate this scientific statement regarding the cardiovascular care of children with aortopathy. Available evidence and expert consensus were combined to create this scientific statement. The most common causes of pediatric aortopathy are reviewed. This document provides a general framework for cardiovascular management of aortopathy in children, while allowing for modification based on the personal and familial characteristics of each child and family.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39129620/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240813021413&v=2.18.0.post9+e462414">39129620</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001265>10.1161/CIR.0000000000001265</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39129620</guid>
<pubDate>Mon, 12 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Shaine A Morris</dc:creator>
<dc:creator>Jonathan N Flyer</dc:creator>
<dc:creator>Anji T Yetman</dc:creator>
<dc:creator>Emilio Quezada</dc:creator>
<dc:creator>Elizabeth S Cappella</dc:creator>
<dc:creator>Harry C Dietz</dc:creator>
<dc:creator>Dianna M Milewicz</dc:creator>
<dc:creator>Maral Ouzounian</dc:creator>
<dc:creator>Christina M Rigelsky</dc:creator>
<dc:creator>Seda Tierney</dc:creator>
<dc:creator>Ronald V Lacro</dc:creator>
<dc:creator>American Heart Association Council on Lifelong Congenital Heart Disease and Heart Health in the Young (Young Hearts); Council on Cardiovascular and Stroke Nursing; Council on Peripheral Vascular Disease; Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; and Council on Cardiovascular Surgery and Anesthesia</dc:creator>
<dc:date>2024-08-12</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Cardiovascular Management of Aortopathy in Children: A Scientific Statement From the American Heart Association</dc:title>
<dc:identifier>pmid:39129620</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001265</dc:identifier>
</item>
<item>
<title>2024 ACC Expert Consensus Decision Pathway on Clinical Assessment, Management, and Trajectory of Patients Hospitalized With Heart Failure Focused Update: A Report of the American College of Cardiology Solution Set Oversight Committee</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39127954/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240813021413&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 2:S0735-1097(24)07449-7. doi: 10.1016/j.jacc.2024.06.002. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39127954/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240813021413&v=2.18.0.post9+e462414">39127954</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.002>10.1016/j.jacc.2024.06.002</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39127954</guid>
<pubDate>Sun, 11 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Writing Committee</dc:creator>
<dc:creator>Steven M Hollenberg</dc:creator>
<dc:creator>Lynne Warner Stevenson</dc:creator>
<dc:creator>Tariq Ahmad</dc:creator>
<dc:creator>Biykem Bozkurt</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:creator>Leslie L Davis</dc:creator>
<dc:creator>Mark H Drazner</dc:creator>
<dc:creator>James N Kirkpatrick</dc:creator>
<dc:creator>Alanna A Morris</dc:creator>
<dc:creator>Robert Lee Page</dc:creator>
<dc:creator>Hasan Khalid Siddiqi</dc:creator>
<dc:creator>Alan B Storrow</dc:creator>
<dc:creator>John R Teerlink</dc:creator>
<dc:date>2024-08-11</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>2024 ACC Expert Consensus Decision Pathway on Clinical Assessment, Management, and Trajectory of Patients Hospitalized With Heart Failure Focused Update: A Report of the American College of Cardiology Solution Set Oversight Committee</dc:title>
<dc:identifier>pmid:39127954</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.002</dc:identifier>
</item>
<item>
<title>2024 Update to the 2020 ACC/AHA Clinical Performance and Quality Measures for Adults With Heart Failure: A Report of the American Heart Association/American College of Cardiology Joint Committee on Performance Measures</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39127953/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240813021413&amp;v=2.18.0.post9+e462414
      <description>This document describes performance measures for heart failure that are appropriate for public reporting or pay-for-performance programs and is meant to serve as a focused update of the "2020 ACC/AHA Clinical Performance and Quality Measures for Adults With Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures." The new performance measures are taken from the "2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 5:S0735-1097(24)07288-7. doi: 10.1016/j.jacc.2024.05.014. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">This document describes performance measures for heart failure that are appropriate for public reporting or pay-for-performance programs and is meant to serve as a focused update of the "2020 ACC/AHA Clinical Performance and Quality Measures for Adults With Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures." The new performance measures are taken from the "2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines" and are selected from the strongest recommendations (Class 1 or Class 3). In contrast, quality measures may not have as much evidence base and generally comprise metrics that might be useful for clinicians and health care organizations for quality improvement but are not yet appropriate for public reporting or pay-for-performance programs. New performance measures include optimal blood pressure control in patients with heart failure with preserved ejection fraction, the use of sodium-glucose cotransporter-2 inhibitors for patients with heart failure with reduced ejection fraction, and the use of guideline-directed medical therapy in hospitalized patients. New quality measures include the use of sodium-glucose cotransporter-2 inhibitors in patients with heart failure with mildly reduced and preserved ejection fraction, the optimization of guideline-directed medical therapy prior to intervention for chronic secondary severe mitral regurgitation, continuation of guideline-directed medical therapy for patients with heart failure with improved ejection fraction, identifying both known risks for cardiovascular disease and social determinants of health, patient-centered counseling regarding contraception and pregnancy risks for individuals with cardiomyopathy, and the need for a monoclonal protein screen to exclude light chain amyloidosis when interpreting a bone scintigraphy scan assessing for transthyretin cardiac amyloidosis.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39127953/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240813021413&v=2.18.0.post9+e462414">39127953</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.014>10.1016/j.jacc.2024.05.014</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39127953</guid>
<pubDate>Sun, 11 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Writing Committee Members</dc:creator>
<dc:creator>Michelle M Kittleson</dc:creator>
<dc:creator>Khadijah Breathett</dc:creator>
<dc:creator>Boback Ziaeian</dc:creator>
<dc:creator>David Aguilar</dc:creator>
<dc:creator>Vanessa Blumer</dc:creator>
<dc:creator>Biykem Bozkurt</dc:creator>
<dc:creator>Rebecca L Diekemper</dc:creator>
<dc:creator>Michael P Dorsch</dc:creator>
<dc:creator>Paul A Heidenreich</dc:creator>
<dc:creator>Corrine Y Jurgens</dc:creator>
<dc:creator>Prateeti Khazanie</dc:creator>
<dc:creator>George Augustine Koromia</dc:creator>
<dc:creator>Harriette G C Van Spall</dc:creator>
<dc:date>2024-08-11</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>2024 Update to the 2020 ACC/AHA Clinical Performance and Quality Measures for Adults With Heart Failure: A Report of the American Heart Association/American College of Cardiology Joint Committee on Performance Measures</dc:title>
<dc:identifier>pmid:39127953</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.014</dc:identifier>
</item>
<item>
<title>The molecular architecture of the nuclear basket</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39127037/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240813021413&amp;v=2.18.0.post9+e462414
      <description>The nuclear pore complex (NPC) is the sole mediator of nucleocytoplasmic transport. Despite great advances in understanding its conserved core architecture, the peripheral regions can exhibit considerable variation within and between species. One such structure is the cage-like nuclear basket. Despite its crucial roles in mRNA surveillance and chromatin organization, an architectural understanding has remained elusive. Using in-cell cryo-electron tomography and subtomogram analysis, we explored...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Aug 5:S0092-8674(24)00780-3. doi: 10.1016/j.cell.2024.07.020. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The nuclear pore complex (NPC) is the sole mediator of nucleocytoplasmic transport. Despite great advances in understanding its conserved core architecture, the peripheral regions can exhibit considerable variation within and between species. One such structure is the cage-like nuclear basket. Despite its crucial roles in mRNA surveillance and chromatin organization, an architectural understanding has remained elusive. Using in-cell cryo-electron tomography and subtomogram analysis, we explored the NPC's structural variations and the nuclear basket across fungi (yeast; S. cerevisiae), mammals (mouse; M. musculus), and protozoa (T. gondii). Using integrative structural modeling, we computed a model of the basket in yeast and mammals that revealed how a hub of nucleoporins (Nups) in the nuclear ring binds to basket-forming Mlp/Tpr proteins: the coiled-coil domains of Mlp/Tpr form the struts of the basket, while their unstructured termini constitute the basket distal densities, which potentially serve as a docking site for mRNA preprocessing before nucleocytoplasmic transport.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39127037/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240813021413&v=2.18.0.post9+e462414">39127037</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.07.020>10.1016/j.cell.2024.07.020</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39127037</guid>
<pubDate>Sat, 10 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Digvijay Singh</dc:creator>
<dc:creator>Neelesh Soni</dc:creator>
<dc:creator>Joshua Hutchings</dc:creator>
<dc:creator>Ignacia Echeverria</dc:creator>
<dc:creator>Farhaz Shaikh</dc:creator>
<dc:creator>Madeleine Duquette</dc:creator>
<dc:creator>Sergey Suslov</dc:creator>
<dc:creator>Zhixun Li</dc:creator>
<dc:creator>Trevor van Eeuwen</dc:creator>
<dc:creator>Kelly Molloy</dc:creator>
<dc:creator>Yi Shi</dc:creator>
<dc:creator>Junjie Wang</dc:creator>
<dc:creator>Qiang Guo</dc:creator>
<dc:creator>Brian T Chait</dc:creator>
<dc:creator>Javier Fernandez-Martinez</dc:creator>
<dc:creator>Michael P Rout</dc:creator>
<dc:creator>Andrej Sali</dc:creator>
<dc:creator>Elizabeth Villa</dc:creator>
<dc:date>2024-08-10</dc:date>
<dc:source>Cell</dc:source>
<dc:title>The molecular architecture of the nuclear basket</dc:title>
<dc:identifier>pmid:39127037</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.07.020</dc:identifier>
</item>
<item>
<title>Angioscopic evaluation of the efficacy of a new excimer laser in in-stent occlusion of a drug eluting stent</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39126341/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240813021413&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 10:ehae512. doi: 10.1093/eurheartj/ehae512. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39126341/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240813021413&v=2.18.0.post9+e462414">39126341</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae512>10.1093/eurheartj/ehae512</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39126341</guid>
<pubDate>Sat, 10 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Takeo Horikoshi</dc:creator>
<dc:creator>Tsuyoshi Kobayashi</dc:creator>
<dc:creator>Akira Sato</dc:creator>
<dc:date>2024-08-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Angioscopic evaluation of the efficacy of a new excimer laser in in-stent occlusion of a drug eluting stent</dc:title>
<dc:identifier>pmid:39126341</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae512</dc:identifier>
</item>
<item>
<title>The need to diversify genomic studies: Insights from Andean highlanders and Amazonians</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39121858/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240813021413&amp;v=2.18.0.post9+e462414
      <description>More globally diverse perspectives are needed in genomic studies and precision medicine practices on non-Europeans. Here, we illustrate this by discussing the distribution of clinically actionable genetic variants involved in drug response in Andean highlanders and Amazonians, considering their environment, history, genetic structure, and historical biases in the perception of biological diversity of Native Americans.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jul 30:S0092-8674(24)00769-4. doi: 10.1016/j.cell.2024.07.009. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">More globally diverse perspectives are needed in genomic studies and precision medicine practices on non-Europeans. Here, we illustrate this by discussing the distribution of clinically actionable genetic variants involved in drug response in Andean highlanders and Amazonians, considering their environment, history, genetic structure, and historical biases in the perception of biological diversity of Native Americans.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39121858/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240813021413&v=2.18.0.post9+e462414">39121858</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.07.009>10.1016/j.cell.2024.07.009</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39121858</guid>
<pubDate>Fri, 09 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Isabela Alvim</dc:creator>
<dc:creator>Carolina Silva-Carvalho</dc:creator>
<dc:creator>Marla Mendes de Aquino</dc:creator>
<dc:creator>Victor Borda</dc:creator>
<dc:creator>Cesar Sanchez</dc:creator>
<dc:creator>Carlos Padilla</dc:creator>
<dc:creator>Omar Cáceres</dc:creator>
<dc:creator>Isabela Rezende-Diniz</dc:creator>
<dc:creator>Julia Saraiva-Duarte</dc:creator>
<dc:creator>Lucas Faria-Costa</dc:creator>
<dc:creator>Meddly L Santolalla</dc:creator>
<dc:creator>Fernanda Rodrigues-Soares</dc:creator>
<dc:creator>Camila Zolini</dc:creator>
<dc:creator>Adrián Llerena</dc:creator>
<dc:creator>Timothy D O'Connor</dc:creator>
<dc:creator>Robert H Gilman</dc:creator>
<dc:creator>Heinner Guio</dc:creator>
<dc:creator>Eduardo Tarazona-Santos</dc:creator>
<dc:date>2024-08-09</dc:date>
<dc:source>Cell</dc:source>
<dc:title>The need to diversify genomic studies: Insights from Andean highlanders and Amazonians</dc:title>
<dc:identifier>pmid:39121858</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.07.009</dc:identifier>
</item>
<item>
<title>Stress-sensitive neural circuits change the gut microbiome via duodenal glands</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39121857/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240813021413&amp;v=2.18.0.post9+e462414
      <description>Negative psychological states impact immunity by altering the gut microbiome. However, the relationship between brain states and microbiome composition remains unclear. We show that Brunner's glands in the duodenum couple stress-sensitive brain circuits to bacterial homeostasis. Brunner's glands mediated the enrichment of gut Lactobacillus species in response to vagus nerve stimulation. Cell-specific ablation of the glands markedly suppressed Lactobacilli counts and heightened vulnerability to...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Aug 1:S0092-8674(24)00779-7. doi: 10.1016/j.cell.2024.07.019. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Negative psychological states impact immunity by altering the gut microbiome. However, the relationship between brain states and microbiome composition remains unclear. We show that Brunner's glands in the duodenum couple stress-sensitive brain circuits to bacterial homeostasis. Brunner's glands mediated the enrichment of gut Lactobacillus species in response to vagus nerve stimulation. Cell-specific ablation of the glands markedly suppressed Lactobacilli counts and heightened vulnerability to infection. In the forebrain, we mapped a vagally mediated, polysynaptic circuit connecting the central nucleus of the amygdala to Brunner's glands. Chronic stress suppressed central amygdala activity and phenocopied the effects of gland lesions. Conversely, excitation of either the central amygdala or parasympathetic vagal neurons activated Brunner's glands and reversed the effects of stress on the gut microbiome and immunity. The findings revealed a tractable brain-body mechanism linking psychological states to host defense.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39121857/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240813021413&v=2.18.0.post9+e462414">39121857</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.07.019>10.1016/j.cell.2024.07.019</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39121857</guid>
<pubDate>Fri, 09 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Hao Chang</dc:creator>
<dc:creator>Matthew H Perkins</dc:creator>
<dc:creator>Leonardo S Novaes</dc:creator>
<dc:creator>Feng Qian</dc:creator>
<dc:creator>Tong Zhang</dc:creator>
<dc:creator>Peter H Neckel</dc:creator>
<dc:creator>Simon Scherer</dc:creator>
<dc:creator>Ruth E Ley</dc:creator>
<dc:creator>Wenfei Han</dc:creator>
<dc:creator>Ivan E de Araujo</dc:creator>
<dc:date>2024-08-09</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Stress-sensitive neural circuits change the gut microbiome via duodenal glands</dc:title>
<dc:identifier>pmid:39121857</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.07.019</dc:identifier>
</item>
<item>
<title>Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8&lt;sup>;+&lt;/sup>; T cells to promote antitumor immunity</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39121849/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240813021413&amp;v=2.18.0.post9+e462414
      <description>Relatlimab (rela; anti-LAG-3) plus nivolumab (nivo; anti-PD-1) is safe and effective for treatment of advanced melanoma. We designed a trial (NCT03743766) where advanced melanoma patients received rela, nivo, or rela+nivo to interrogate the immunologic mechanisms of rela+nivo. Analysis of biospecimens from this ongoing trial demonstrated that rela+nivo led to enhanced capacity for CD8^(+) T cell receptor signaling and altered CD8^(+) T cell differentiation, leading to heightened cytotoxicity...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Aug 8;187(16):4373-4388.e15. doi: 10.1016/j.cell.2024.06.036.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Relatlimab (rela; anti-LAG-3) plus nivolumab (nivo; anti-PD-1) is safe and effective for treatment of advanced melanoma. We designed a trial (NCT03743766) where advanced melanoma patients received rela, nivo, or rela+nivo to interrogate the immunologic mechanisms of rela+nivo. Analysis of biospecimens from this ongoing trial demonstrated that rela+nivo led to enhanced capacity for CD8<sup>+</sup> T cell receptor signaling and altered CD8<sup>+</sup> T cell differentiation, leading to heightened cytotoxicity despite the retention of an exhaustion profile. Co-expression of cytotoxic and exhaustion signatures was driven by PRDM1, BATF, ETV7, and TOX. Effector function was upregulated in clonally expanded CD8<sup>+</sup> T cells that emerged after rela+nivo. A rela+nivo intratumoral CD8<sup>+</sup> T cell signature was associated with a favorable prognosis. This intratumoral rela+nivo signature was validated in peripheral blood as an elevated frequency of CD38<sup>+</sup>TIM3<sup>+</sup>CD8<sup>+</sup> T cells. Overall, we demonstrated that cytotoxicity can be enhanced despite the retention of exhaustion signatures, which will inform future therapeutic strategies.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39121849/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240813021413&v=2.18.0.post9+e462414">39121849</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.06.036>10.1016/j.cell.2024.06.036</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39121849</guid>
<pubDate>Fri, 09 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Anthony R Cillo</dc:creator>
<dc:creator>Carly Cardello</dc:creator>
<dc:creator>Feng Shan</dc:creator>
<dc:creator>Lilit Karapetyan</dc:creator>
<dc:creator>Sheryl Kunning</dc:creator>
<dc:creator>Cindy Sander</dc:creator>
<dc:creator>Elizabeth Rush</dc:creator>
<dc:creator>Arivarasan Karunamurthy</dc:creator>
<dc:creator>Ryan C Massa</dc:creator>
<dc:creator>Anjali Rohatgi</dc:creator>
<dc:creator>Creg J Workman</dc:creator>
<dc:creator>John M Kirkwood</dc:creator>
<dc:creator>Tullia C Bruno</dc:creator>
<dc:creator>Dario A A Vignali</dc:creator>
<dc:date>2024-08-09</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8&lt;sup>;+&lt;/sup>; T cells to promote antitumor immunity</dc:title>
<dc:identifier>pmid:39121849</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.06.036</dc:identifier>
</item>
<item>
<title>LAG-3 and PD-1 synergize on CD8&lt;sup>;+&lt;/sup>; T cells to drive T cell exhaustion and hinder autocrine IFN-γ-dependent anti-tumor immunity</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39121848/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240813021413&amp;v=2.18.0.post9+e462414
      <description>Overcoming immune-mediated resistance to PD-1 blockade remains a major clinical challenge. Enhanced efficacy has been demonstrated in melanoma patients with combined nivolumab (anti-PD-1) and relatlimab (anti-LAG-3) treatment, the first in its class to be FDA approved. However, how these two inhibitory receptors synergize to hinder anti-tumor immunity remains unknown. Here, we show that CD8^(+) T cells deficient in both PD-1 and LAG-3, in contrast to CD8^(+) T cells lacking either receptor,...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Aug 8;187(16):4355-4372.e22. doi: 10.1016/j.cell.2024.07.016.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Overcoming immune-mediated resistance to PD-1 blockade remains a major clinical challenge. Enhanced efficacy has been demonstrated in melanoma patients with combined nivolumab (anti-PD-1) and relatlimab (anti-LAG-3) treatment, the first in its class to be FDA approved. However, how these two inhibitory receptors synergize to hinder anti-tumor immunity remains unknown. Here, we show that CD8<sup>+</sup> T cells deficient in both PD-1 and LAG-3, in contrast to CD8<sup>+</sup> T cells lacking either receptor, mediate enhanced tumor clearance and long-term survival in mouse models of melanoma. PD-1- and LAG-3-deficient CD8<sup>+</sup> T cells were transcriptionally distinct, with broad TCR clonality and enrichment of effector-like and interferon-responsive genes, resulting in enhanced IFN-γ release indicative of functionality. LAG-3 and PD-1 combined to drive T cell exhaustion, playing a dominant role in modulating TOX expression. Mechanistically, autocrine, cell-intrinsic IFN-γ signaling was required for PD-1- and LAG-3-deficient CD8<sup>+</sup> T cells to enhance anti-tumor immunity, providing insight into how combinatorial targeting of LAG-3 and PD-1 enhances efficacy.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39121848/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240813021413&v=2.18.0.post9+e462414">39121848</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.07.016>10.1016/j.cell.2024.07.016</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39121848</guid>
<pubDate>Fri, 09 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Lawrence P Andrews</dc:creator>
<dc:creator>Samuel C Butler</dc:creator>
<dc:creator>Jian Cui</dc:creator>
<dc:creator>Anthony R Cillo</dc:creator>
<dc:creator>Carly Cardello</dc:creator>
<dc:creator>Chang Liu</dc:creator>
<dc:creator>Erin A Brunazzi</dc:creator>
<dc:creator>Andrew Baessler</dc:creator>
<dc:creator>Bingxian Xie</dc:creator>
<dc:creator>Sheryl R Kunning</dc:creator>
<dc:creator>Shin Foong Ngiow</dc:creator>
<dc:creator>Yinghui Jane Huang</dc:creator>
<dc:creator>Sasikanth Manne</dc:creator>
<dc:creator>Arlene H Sharpe</dc:creator>
<dc:creator>Greg M Delgoffe</dc:creator>
<dc:creator>E John Wherry</dc:creator>
<dc:creator>John M Kirkwood</dc:creator>
<dc:creator>Tulia C Bruno</dc:creator>
<dc:creator>Creg J Workman</dc:creator>
<dc:creator>Dario A A Vignali</dc:creator>
<dc:date>2024-08-09</dc:date>
<dc:source>Cell</dc:source>
<dc:title>LAG-3 and PD-1 synergize on CD8&lt;sup>;+&lt;/sup>; T cells to drive T cell exhaustion and hinder autocrine IFN-γ-dependent anti-tumor immunity</dc:title>
<dc:identifier>pmid:39121848</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.07.016</dc:identifier>
</item>
<item>
<title>LAG-3 sustains TOX expression and regulates the CD94/NKG2-Qa-1b axis to govern exhausted CD8 T cell NK receptor expression and cytotoxicity</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39121847/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240813021413&amp;v=2.18.0.post9+e462414
      <description>Exhausted CD8 T (T(ex)) cells in chronic viral infection and cancer have sustained co-expression of inhibitory receptors (IRs). T(ex) cells can be reinvigorated by blocking IRs, such as PD-1, but synergistic reinvigoration and enhanced disease control can be achieved by co-targeting multiple IRs including PD-1 and LAG-3. To dissect the molecular changes intrinsic when these IR pathways are disrupted, we investigated the impact of loss of PD-1 and/or LAG-3 on T(ex) cells during chronic infection....</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Aug 8;187(16):4336-4354.e19. doi: 10.1016/j.cell.2024.07.018.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Exhausted CD8 T (T<sub>ex</sub>) cells in chronic viral infection and cancer have sustained co-expression of inhibitory receptors (IRs). T<sub>ex</sub> cells can be reinvigorated by blocking IRs, such as PD-1, but synergistic reinvigoration and enhanced disease control can be achieved by co-targeting multiple IRs including PD-1 and LAG-3. To dissect the molecular changes intrinsic when these IR pathways are disrupted, we investigated the impact of loss of PD-1 and/or LAG-3 on T<sub>ex</sub> cells during chronic infection. These analyses revealed distinct roles of PD-1 and LAG-3 in regulating T<sub>ex</sub> cell proliferation and effector functions, respectively. Moreover, these studies identified an essential role for LAG-3 in sustaining TOX and T<sub>ex</sub> cell durability as well as a LAG-3-dependent circuit that generated a CD94/NKG2<sup>+</sup> subset of T<sub>ex</sub> cells with enhanced cytotoxicity mediated by recognition of the stress ligand Qa-1b, with similar observations in humans. These analyses disentangle the non-redundant mechanisms of PD-1 and LAG-3 and their synergy in regulating T<sub>ex</sub> cells.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39121847/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240813021413&v=2.18.0.post9+e462414">39121847</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.07.018>10.1016/j.cell.2024.07.018</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39121847</guid>
<pubDate>Fri, 09 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Shin Foong Ngiow</dc:creator>
<dc:creator>Sasikanth Manne</dc:creator>
<dc:creator>Yinghui Jane Huang</dc:creator>
<dc:creator>Tarek Azar</dc:creator>
<dc:creator>Zeyu Chen</dc:creator>
<dc:creator>Divij Mathew</dc:creator>
<dc:creator>Qingzhou Chen</dc:creator>
<dc:creator>Omar Khan</dc:creator>
<dc:creator>Jennifer E Wu</dc:creator>
<dc:creator>Victor Alcalde</dc:creator>
<dc:creator>Ahron J Flowers</dc:creator>
<dc:creator>Sean McClain</dc:creator>
<dc:creator>Amy E Baxter</dc:creator>
<dc:creator>Makoto Kurachi</dc:creator>
<dc:creator>Junwei Shi</dc:creator>
<dc:creator>Alexander C Huang</dc:creator>
<dc:creator>Josephine R Giles</dc:creator>
<dc:creator>Arlene H Sharpe</dc:creator>
<dc:creator>Dario A A Vignali</dc:creator>
<dc:creator>E John Wherry</dc:creator>
<dc:date>2024-08-09</dc:date>
<dc:source>Cell</dc:source>
<dc:title>LAG-3 sustains TOX expression and regulates the CD94/NKG2-Qa-1b axis to govern exhausted CD8 T cell NK receptor expression and cytotoxicity</dc:title>
<dc:identifier>pmid:39121847</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.07.018</dc:identifier>
</item>
<item>
<title>Guidelines for minimal information on cellular senescence experimentation in vivo</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39121846/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240813021413&amp;v=2.18.0.post9+e462414
      <description>Cellular senescence is a cell fate triggered in response to stress and is characterized by stable cell-cycle arrest and a hypersecretory state. It has diverse biological roles, ranging from tissue repair to chronic disease. The development of new tools to study senescence in vivo has paved the way for uncovering its physiological and pathological roles and testing senescent cells as a therapeutic target. However, the lack of specific and broadly applicable markers makes it difficult to identify...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Aug 8;187(16):4150-4175. doi: 10.1016/j.cell.2024.05.059.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Cellular senescence is a cell fate triggered in response to stress and is characterized by stable cell-cycle arrest and a hypersecretory state. It has diverse biological roles, ranging from tissue repair to chronic disease. The development of new tools to study senescence in vivo has paved the way for uncovering its physiological and pathological roles and testing senescent cells as a therapeutic target. However, the lack of specific and broadly applicable markers makes it difficult to identify and characterize senescent cells in tissues and living organisms. To address this, we provide practical guidelines called "minimum information for cellular senescence experimentation in vivo" (MICSE). It presents an overview of senescence markers in rodent tissues, transgenic models, non-mammalian systems, human tissues, and tumors and their use in the identification and specification of senescent cells. These guidelines provide a uniform, state-of-the-art, and accessible toolset to improve our understanding of cellular senescence in vivo.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39121846/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240813021413&v=2.18.0.post9+e462414">39121846</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.05.059>10.1016/j.cell.2024.05.059</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39121846</guid>
<pubDate>Fri, 09 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Mikolaj Ogrodnik</dc:creator>
<dc:creator>Juan Carlos Acosta</dc:creator>
<dc:creator>Peter D Adams</dc:creator>
<dc:creator>Fabrizio d'Adda di Fagagna</dc:creator>
<dc:creator>Darren J Baker</dc:creator>
<dc:creator>Cleo L Bishop</dc:creator>
<dc:creator>Tamir Chandra</dc:creator>
<dc:creator>Manuel Collado</dc:creator>
<dc:creator>Jesus Gil</dc:creator>
<dc:creator>Vassilis Gorgoulis</dc:creator>
<dc:creator>Florian Gruber</dc:creator>
<dc:creator>Eiji Hara</dc:creator>
<dc:creator>Pidder Jansen-Dürr</dc:creator>
<dc:creator>Diana Jurk</dc:creator>
<dc:creator>Sundeep Khosla</dc:creator>
<dc:creator>James L Kirkland</dc:creator>
<dc:creator>Valery Krizhanovsky</dc:creator>
<dc:creator>Tohru Minamino</dc:creator>
<dc:creator>Laura J Niedernhofer</dc:creator>
<dc:creator>João F Passos</dc:creator>
<dc:creator>Nadja A R Ring</dc:creator>
<dc:creator>Heinz Redl</dc:creator>
<dc:creator>Paul D Robbins</dc:creator>
<dc:creator>Francis Rodier</dc:creator>
<dc:creator>Karin Scharffetter-Kochanek</dc:creator>
<dc:creator>John M Sedivy</dc:creator>
<dc:creator>Ewa Sikora</dc:creator>
<dc:creator>Kenneth Witwer</dc:creator>
<dc:creator>Thomas von Zglinicki</dc:creator>
<dc:creator>Maximina H Yun</dc:creator>
<dc:creator>Johannes Grillari</dc:creator>
<dc:creator>Marco Demaria</dc:creator>
<dc:date>2024-08-09</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Guidelines for minimal information on cellular senescence experimentation in vivo</dc:title>
<dc:identifier>pmid:39121846</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.05.059</dc:identifier>
</item>
<item>
<title>Prying the lid open: Atomic-level insights on sialoglycan-TMPRSS2 coordination in HKU1 entry</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39121845/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240813021413&amp;v=2.18.0.post9+e462414
      <description>The pre-fusion coronavirus HKU1 spike binds host sialoglycans and proteinaceous receptor TMPRSS2 for cell entry. In this issue of Cell, three papers by Fernández et al., McCallum et al., and Wang et al. provide structural information on HKU1 spike interactions with host receptors, providing insights into its multi-step opening.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Aug 8;187(16):4147-4149. doi: 10.1016/j.cell.2024.07.007.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The pre-fusion coronavirus HKU1 spike binds host sialoglycans and proteinaceous receptor TMPRSS2 for cell entry. In this issue of Cell, three papers by Fernández et al., McCallum et al., and Wang et al. provide structural information on HKU1 spike interactions with host receptors, providing insights into its multi-step opening.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39121845/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240813021413&v=2.18.0.post9+e462414">39121845</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.07.007>10.1016/j.cell.2024.07.007</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39121845</guid>
<pubDate>Fri, 09 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Ruth J Parsons</dc:creator>
<dc:creator>Priyamvada Acharya</dc:creator>
<dc:date>2024-08-09</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Prying the lid open: Atomic-level insights on sialoglycan-TMPRSS2 coordination in HKU1 entry</dc:title>
<dc:identifier>pmid:39121845</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.07.007</dc:identifier>
</item>





























</channel>
</rss>